AstraZeneca PLC (AZN)vsPrecision Optics Corporation, Inc. Common stock (POCI)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
POCI
Precision Optics Corporation, Inc. Common stock
$5.53
+0.55%
HEALTHCARE · Cap: $62.17M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 208753% more annual revenue ($60.44B vs $28.94M). AZN leads profitability with a 17.2% profit margin vs -17.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
POCI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-19.1%
Fair Value
$4.20
Current Price
$5.53
$1.33 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 108.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -29.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : POCI
The strongest argument for POCI centers on Revenue Growth, Debt/Equity. Revenue growth of 108.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : POCI
The primary concerns for POCI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while POCI is a hypergrowth play — different risk/reward profiles.
POCI carries more volatility with a beta of 0.23 — expect wider price swings.
POCI is growing revenue faster at 108.0% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 31/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Precision Optics Corporation, Inc. Common stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Precision Optics Corporation, Inc. designs, develops, manufactures, and sells specialized optical and lighting systems and related components primarily in the United States and the European Economic Area. The company is headquartered in Gardner, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?